Deliverable

D6.1 - Plan for Dissemination, Communication and Exploitation of Results – Second version (M18)

WP:	**6**
Document Type:	**R**
Version:	**2**
Project Information:	Towards a sustainable pharmaceutical production
Grant Agreement n°:	101057816
Project Dates:	**June 1st 2022 – May 31st 2026**

TRANS PHARM

Funded by the European Union

DOCUMENT INFORMATION

Project Name	TransPharm
Deliverable Title/Number	D6.1
Description	Plan for Dissemination, Communication and Exploitation of Results
Lead beneficiary	Ecologic Institut gemeinnützige GmbH
Lead Authors	Rodrigo Vidaurre
Contributors	Marie Gaillard, Chiara Mazzetti
Contractual delivery date:	30/11/22 (M6)
Actual delivery date:	14/12/22 (M7) – Updated 14/02/24 (M21)
Sensitivity	PU - Public

DOCUMENT APPROVAL

NAME	ORGANISATION	ROLE	ACTION	DATE
Rodrigo Vidaurre	Ecologic	WP leader	Approved	14/02/2024
Guadalupe Vinado	Benkei	PMO	Approved	14/02/2024
Christian Stevens	UGent	Coordinator	Approved	14/02/2024

DOCUMENT HISTORY

VERSION	DATE	MODIFICATIONS	AUTHORS
V1	28/11/22	First draft	Rodrigo Vidaurre
V2	14/12/22	Update after review partners	Rodrigo Vidaurre
V3	24/01/24	Update	Rodrigo Vidaurre
V4	14/02/24	Update after review partners	Guadalupe Vinado
VF	14/02/24	Coordinator approval	Christian Stevens

To request a change to this document, contact the Document Author.

CONFIGURATION MANAGEMENT

NATURE OF DELIVERABLE		
R	Document, report (excluding the periodic and final reports)	
DEC	Websites, patents filing, press & media actions, videos, etc.	X
DEM	Demonstrator, pilot, prototype, plan designs	
OTHER	Software, technical diagram, algorithms, models, etc.	

ETHICS	Deliverables related to ethics issues.	
DATA	Data sets, microdata, etc	
DMP	Data Management Plan	
SCURITY	Deliverables related to security issues	

DISSEMINATION LEVEL		
PU	Public, fully open, e.g., web (Deliverables flagged as public will be automatically published in CORDIS projects.)	**X**
SEN	Sensitive, limited under the conditions of the Grant Agreement	
Classified EU-R	EU RESTRICTED under the Commission Decision No2015/444	
Classified EU-C	CONFIDENTIAL under the Commission Decision No2015/444	
Classified EU-S	EU SECRET under the Commission Decision No2015/444	

ACRONYM/ABBREVIATIONS	
API	Active Pharmaceutical Ingredient
CA	Consortium Agreement (contractual document between members of the consortium)
DoA	Description of Action (technical annex to the Grant Agreement)
EC	European Commission
EU	European Union
FTP	Funding and Tenders Portal: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home
GA	Grant Agreement (contractual document between EC and beneficiaries)
IPR	Intellectual Property Rights
KO	Kick Off (meeting)
MC	Management Coordinator
MTA	Milestones Trend Analysis
PC	Project Coordinator
PMO	Project Management Office
TL	Task Leaders
WP	Work Package
WPL	Work Package Leaders

Acknowledgements

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement N° 101057816. The authors would like to thank European Commission for the funding.

Disclaimer

CONTENTS

LIST OF TABLES

TABLE OF FIGURES

1 EXECUTIVE SUMMARY

The research project “TransPharm - Towards a sustainable pharmaceutical production” is a four-year Research and Innovation Action (RIA) which has been accepted for funding with the European Union's Horizon Europe Framework Programme (HE/2021-2027), under Grant Agreement n°101057816.

This document presents the second version of the project’s Plan for Communication, Dissemination and Exploitation of Results, first developed in Month 6 of the project and to be updated in Months 18, 30 and 42. This report represents the first update and has been finalised in Month 20.

2 DESCRIPTION OF THE DELIVERABLE OBJECTIVE AND CONTENT

The research project *"TransPharm - Towards a sustainable pharmaceutical production"* is a four-year Research and Innovation Action (RIA) which has been accepted for funding with the European Union's Horizon Europe Framework Programme (HE/2021-2027), under Grant Agreement n°101057816. This document presents the second, updated version of the project's **Plan for Communication, Dissemination and Exploitation of Results**. The first version was developed in Month 6 of the project; this version corresponds to the update due in Month 18. There will be further updates in Months 30 and 42.

Work Package 6's name – *"Stakeholder engagement, communication, dissemination, exploitation and training activities"* – provides already a summary of the work package's different areas of action. Table 1 presents an overview of the WP's tasks and their main objectives.

Table 1: Overview of WP6's tasks and their objectives.

Tasks	Main objective
Task 6.1: Plan for Stakeholder Engagement, Dissemination and Exploitation of Results	Development and update of planning for tasks 6.3 - 6.6.
Task 6.2: Data Management Plan	Development and update of project's Data Management Plan.
Task 6.3: Stakeholder engagement	Engaging with stakeholders (researchers, regulators, industry) to provide relevant inputs to WPs 2, 3 and 5 to increase relevance of task's outputs.
Task 6.4: Communication and dissemination	Sharing project news and outcomes with target groups.
Task 6.5: Exploitation management of project results	Facilitating exploitation of project results.
Task 6.6: Training activities	Developing training materials targeting industry / academia, healthcare actors, and potentially the broader public and water managers

This report (D6.1) presents the updated outcomes and planning for Tasks 6.4 to 6.6. (A separate deliverable (D6.8) presents the planning for Task 6.3.) Chapter 3 presents an overview of the project's communication and dissemination actions performed within *Task 6.4: Communication and dissemination* and *Task 6.6: Training activities*. Chapter 4 provides an overview of the actions related to the exploitation of project results carried out within *Task 6.5: Exploitation management of project results*.

TransPharm's **main goals** are:

- Help move towards a more sustainable European pharmaceutical production of Active Pharmaceutical Ingredients (APIs)
- To develop more sustainable and greener APIs that simultaneously reduce the environmental footprint and the dependence on third countries for API production.
- Deliver digital tools and guidelines, also based on artificial intelligence, for the development of greener pharmaceutical products and APIs, as well as models to judge their impact.
- Elaborate business cases for sustainable pharmaceutical products or APIs and what is needed to bring them to the market.
- Transfer key project results and knowledge towards targeted stakeholders.

TransPharm aims to achieve the following **breakthroughs**:

- The project will propose a multi-level approach to provide researchers and regulators with a **better understanding of the environmental impact of pharmaceuticals**. Tools and guidelines will be developed and shared – together with the project key results - with targeted stakeholders such as researchers and regulators. Besides them, the wider community will be targeted to foster the understanding of the environmental impact of pharmaceuticals.
- The project's objective is to generate scientific evidence related to the development, production, use and disposal of pharmaceuticals, so that public authorities can inform pharmaceutical strategies and policies based on scientific evidence.
- The project will contribute to the development and future use of greener pharmaceuticals by
    i. Creating a centre of excellence, with training actions dedicated to the young generation and researchers,
    ii. Provide scientific evidence that might help to the development of new standards,
    iii. Providing scientific evidence so that public authorities can inform pharmaceutical strategies and polices,
    iv. Empowering the healthcare sector and general public to a more sustainable use of pharmaceuticals, including sustainable procurement of pharmaceuticals.

It will assure **reliable access to key manufacturing capacity and will support bringing back production to Europe**. The EU will create an autonomous leadership position with on demand, faster, cheaper and more sustainable manufacturing of medicines products.

3 COMMUNICATION AND DISSEMINATION ACTIONS: OVERVIEW, TIMEPLAN, RESPONSIBILITIES

With the aim of facilitating uptake of project results, TransPharm outcomes will be communicated to a variety of relevant stakeholders (incl. industry, academia, and policy makers) via targeted communication actions. The wide-ranging actions span from conducting training events and producing training materials to organising conference events and publishing a white paper for policy makers.

Table 2 below provides an overview of already finalised actions related to communication and dissemination, whereas Table 3 provides an overview of upcoming actions.

Table 2: Overview of finalised TransPharm communication and dissemination actions / Status at M18

ACTIONS	PARTNER RESPONSIBLE
Set-up of communications tools internal to project (Sharepoint, email distribution lists)	UGent
Development of a Visual Identity for the project	Ecologic
Development of templates for project outputs (Powerpoint template, Word template (basic and deliverable), poster templates (landscape and portrait), Newsletter template)	Ecologic
Establishment of social media communication accounts (Twitter, LinkedIn, Instagram)	UGent
Set-up of a project website	UGent
Official PowerPoint presentation of the TransPharm project	UGent
2 press releases (including project's Newsletter #1)	UGent / Benkei
Establishing Scientific Advisory Board	UGent / Benkei
1st project workshop	RIVM / RU / LEUPHANA / Ecologic
6 poster presentations	Various
9 oral contributions	Various
1 published manuscript	UGent

Table 3: Overview of upcoming TransPharm communication and dissemination actions / Status at M18

ACTIONS		SPECIFICATIONS	PARTNER RESPONSIBLE	DUE DATE
Elaboration of a white paper summarising scientific evidence for the development of greener pharmaceuticals		Project's outputs, guidelines, rules and tools	**UGent**	M44 (beta version in M38)
Yearly training events / workshops w/ healthcare value chain and healthcare sector actors (2 physical events + 2 webinars)	Open demonstration 1		**LEU**	M24 (tbc)
	Open demonstration 2		tbc	M36 (tbc)
	Final Symposium	15 industrial partners	**Orion**	M48
Training blocks focused on 4 key stakeholder groups (industry, regulators, academia, general public)		Sustainable choices for pharmaceuticals (w/ themes from WP2,3&4)	**UoY** (w/ support from ECO, LEU, UGent, RIVM)	M48
		Water management	**UoY** (w/ support from RU, ECO, RIVM)	
One video of awareness campaign (as part of general public training module)		Highlight the environmental impact of pharmaceuticals	**RIVM + ECO**	M46
Project newsletters (incl. short public summary / year)		Once-yearly newsletters	**UGent**	M24; M36; M48
Open science publications		15 publications or more	All	By M48
2 specific communications		Format of communications to be defined. Options include journal or magazine articles, holding presentations at meetings convened by EWRA / EUREAU, etc.	**RU, RIVM, ECO**	By M48
10 presentations at relevant international conferences, tradeshows and/or fairs		Projects results presented in conference participation	All	By M48

Over the last eight months WP6 work has focused strongly on the development of training materials for academia / industry. The following figures provide an overview of the planning approach involving all project partners in the development of training materials, with a mind-map cutout showing the responsibilities for Module 1 – Chapter 1, and a Gantt chart overview of the process. The development of this part of the training materials is expected to be finalised by August 2024.



Figure 3-1: Mindmap cutout with an overview of the three training modules for academia / industry and showing responsibilities for Module 1 – Chapter 1.



Figure 3-2: Gantt chart overview of the training materials development

In addition to the project's own communication and dissemination actions, TransPharm has initiated communication with sister projects funded under the same Horizon Europe call to develop synergies and joint communication activities. It is for instance foreseen that sister project representatives participate in the yearly training events / workshops.

4 EXPLOITATION OF PROJECT RESULTS: ACTIONS' OVERVIEW, TIMEPLAN, RESPONSIBILITIES

Exploitation is the utilisation of results in further research activities other than those covered by the action concerned, or in developing, creating and marketing a product or process, or in creating and providing a service or standardisation of activities.

In addition to the four Key Exploitable Results (KERs) identified in the first version of this report, two additional ones were identified over the last 12 months, bringing them up to a total of six KERs. Three of these KERs are currently classified as leading to commercially exploitable results, whereas the three remaining are currently seen as public. The following table provides an overview of the KERs, the partners involved and their type.

Table 4: Overview of project Key Exploitable Results, involved partners and KER type.

Key Exploitable Result (KER)	Partners involved in KER development	Type of KER (commercial / public)
Software toolkit for multistep chemistry	UGENT	Licensing (commercial) or Open Source + OA data (public)
Assessment tools for sustainability, ecotoxicity, environmental degradation and human safety	RU, UH, RIVM	Public + OA data
Prediction tools for sustainability, ecotoxicity, environmental degradation and human safety	RU, UH, UGENT	Public + OA data
New molecules	UGENT, LEU, CIRCA	Patents (commercial)
New production routes for API	UGENT, LEU, CIRCA, UH, KELADA, ORION, LIOS	Patents and industrial know-how (commercial)
Training platform	UoY, ECOLOGIC, LEU	Public

The exploitation activities will be based on these 6 KERs and will enable the development of the different plans listed below.

Table 5: Overview of exploitation-activity related plans / Status M18

ACTIONS	SPECIFICATIONS	PARTNER RESPONSIBLE	DUE DATE
Exploitation Roadmap and Business Plans	This will provide guidance on the exploitation of the products and services through networking analysis, analysis of business models, routes for exploitation, the target user groups and markets and competitor analysis. This will facilitate appropriate management of the knowledge generated in the project and protection of the intellectual property generated. The plan will identify the potential of the TransPharm deliverables, the demand and target groups by investigating:	**Benkei**	M48
Products/service potential	Identification of products or services that have potential for commercial exploitation.	**Benkei**	M48
Market Potential	Identification of potential users (target groups) of products or services. This will be carried out by engaging with stakeholders to ascertain their needs and interests.	**Benkei**	M48

This set of actions will be reviewed at regular intervals by WP representatives as well as by members of the Scientific Advisory Board, who have been identified as being knowledgeable in the relevant technical areas. This will inform Task 6.5 (M12-48) led by Benkei with input from all partners.